At this time, the company appears to be overvalued. ResMed Inc holds a recent Real Value of $254.67 per share. The prevailing price of the company is $271.63. Our model determines the value of ResMed Inc from analyzing the company fundamentals such as Return On Equity of 0.26, operating margin of 0.35 %, and Shares Outstanding of 145.68 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ResMed's valuation include:
Price Book
6.2603
Enterprise Value
39 B
Enterprise Value Ebitda
18.67
Price Sales
7.3449
Forward PE
24.6914
Overvalued
Today
271.63
Please note that ResMed's price fluctuation is very steady at this time. Calculation of the real value of ResMed Inc is based on 3 months time horizon. Increasing ResMed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ResMed stock is determined by what a typical buyer is willing to pay for full or partial control of ResMed Inc. Since ResMed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ResMed Stock. However, ResMed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical
Market 271.63
Real 254.67
Target 297.47
Hype 271.34
The real value of ResMed Stock, also known as its intrinsic value, is the underlying worth of ResMed Inc Company, which is reflected in its stock price. It is based on ResMed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ResMed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ResMed Inc helps investors to forecast how ResMed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ResMed more accurately as focusing exclusively on ResMed's fundamentals will not take into account other important factors:
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ResMed's intrinsic value based on its ongoing forecasts of ResMed's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ResMed's closest peers. If more than one evaluation category is relevant for ResMed we suggest using both methods to arrive at a better estimate.
ResMed Cash
1.46 Billion
ResMed Revenue by Product
ResMed Total Value Analysis
ResMed Inc is at this time expected to have company total value of 39 B with market capitalization of 39.65 B, debt of 851.81 M, and cash on hands of 1.21 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the ResMed fundamentals before making security assessment based on enterprise value of the company
About 67.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.8. ResMed Inc recorded earning per share (EPS) of 10.1. The entity last dividend was issued on the 12th of February 2026. The firm had 2:1 split on the 31st of August 2010. Based on the measurements of operating efficiency obtained from ResMed's historical financial statements, ResMed Inc may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ResMed has an asset utilization ratio of 62.96 percent. This indicates that the Company is making $0.63 for each dollar of assets. An increasing asset utilization means that ResMed Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Dot-com Bubble
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Interest Hikes
ResMed Profitability Analysis
Based on the measurements of profitability obtained from ResMed's financial statements, ResMed Inc may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess ResMed's ability to earn profits and add value for shareholders.
Net Income
First Reported
1992-09-30
Previous Quarter
348.5 M
Current Value
392.6 M
Quarterly Volatility
93.6 M
Dot-com Bubble
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Interest Hikes
The current year's Gross Profit is expected to grow to about 3.7 B, whereas Pretax Profit Margin is forecasted to decline to 0.18.
For ResMed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ResMed Inc to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ResMed utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ResMed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ResMed over time as well as its relative position and ranking within its peers.
ResMed Earnings per Share Projection vs Actual
The next projected EPS of ResMed is estimated to be 2.757225 with future projections ranging from a low of 2.5875 to a high of 2.8071. ResMed's most recent 12-month trailing earnings per share (EPS TTM) is at 10.1. Please be aware that the consensus of earnings estimates for ResMed Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
Dot-com Bubble
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Interest Hikes
ResMed is projected to generate 2.757225 in earnings per share on the 30th of June 2026. ResMed earnings estimates show analyst consensus about projected ResMed EPS (Earning Per Share). It derives the highest and the lowest estimates based on ResMed's historical volatility. Many public companies, such as ResMed, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.
ResMed Earnings Estimation Breakdown
The calculation of ResMed's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ResMed is estimated to be 2.757225 with the future projection ranging from a low of 2.5875 to a high of 2.8071. Please be aware that this consensus of annual earnings estimates for ResMed Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
2.59
Lowest
Expected EPS
2.757225
2.81
Highest
ResMed Earnings Projection Consensus
Suppose the current estimates of ResMed's value are higher than the current market price of the ResMed stock. In this case, investors may conclude that ResMed is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ResMed's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts
Historical Accuracy
Last Reported EPS
Estimated EPS for 30th of June 2026
Current EPS (TTM)
19
93.55%
0.0
2.757225
10.1
ResMed Ownership Allocation
ResMed owns a total of 145.68 Million outstanding shares. Over half of ResMed's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that on June 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of ResMed Inc's common stock.
ResMed Profitability Analysis
The company reported the last year's revenue of 5.15 B. Total Income to common stockholders was 1.4 B with profit before taxes, overhead, and interest of 3.32 B.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ResMed's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ResMed and how it compares across the competition.
About ResMed Valuation
The stock valuation mechanism determines ResMed's current worth on a weekly basis. Our valuation model uses a comparative analysis of ResMed. We calculate exposure to ResMed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ResMed's related companies.
ResMed's stock price is the clearest measure of market expectations about its performance. Without stock valuation, investors cannot independently discern whether ResMed's value is low or high relative to the company's performance and growth projections. Determining the market value of ResMed can be done in different ways, such as multiplying its stock price by its outstanding shares.
A single share of ResMed represents a small ownership stake in the entity. As a stockholder of ResMed, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
ResMed Dividends Analysis For Valuation
At present, ResMed's Dividend Payout Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to 4.13, whereas Dividends Paid is forecasted to decline to about 211.7 M. . At present, ResMed's Price Earnings Ratio is projected to slightly grow based on the last few years of reporting.
There are various types of dividends ResMed can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of ResMed shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from ResMed Inc directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When ResMed pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of ResMed by the value of the dividends paid out.
ResMed Growth Indicators
Investing in growth stocks can be very risky. If the company such as ResMed does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding
147.3 M
Quarterly Earnings Growth Y O Y
0.145
Forward Price Earnings
24.6914
ResMed Current Valuation Indicators
Valuation refers to the process of determining the present value of ResMed Inc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ResMed we look at many different elements of the entity such as ResMed's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ResMed, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ResMed's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ResMed's worth.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.